Hyperplasia in Medical Technology

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

... from placebo and the rate of endometrial hyperplasia in doses being considered for therapeutic use was ... of the SMART-1 trial was incidence of endometrial hyperplasia at one year. Secondary end points included bone ... use were associated with rates of endometrial hyperplasia <1%. These rates were not significantly ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

... channel protein), to treat benign prostatic hyperplasia (BPH). D-3263 demonstrated the ability to reduce ... (p=0.004) of mean prostate weight and prostate hyperplasia with evidence of a dose response. In addition, ... system. It is over-expressed in prostate hyperplasia and multiple types of cancer including prostate ...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

... applicability to multiple types of cancer as well as to benign prostatic hyperplasia (BPH)," stated Mark Frohlich, M.D., senior vice president of clinical ... a gland in the male reproductive system. It is over-expressed in prostate hyperplasia and multiple types of cancer including prostate cancer, breast cancer, ...

Light Sciences Oncology Raises $40.1 Million in Series C Financing

... Colorectal Cancer and Phase I/II and Phase IIa Benign Prostatic hyperplasia Studies BELLEVUE, Wash., July 15 /PRNewswire/ -- Light Sciences ... Litx platform to include benign neoplasms such as benign prostatic hyperplasia (BPH), neurofibromas, and uterine fibroids, as well as vascular disease ...

Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate

... announced that it has begun treatment of patients with benign prostatic hyperplasia (BPH), or enlargement of the prostate, using Light Infusion Therapy(TM) ... Litx platform to include benign neoplasms such as benign prostatic hyperplasia (BPH), neurofibromas, and uterine fibroids, as well as vascular disease ...

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

... involving silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement) and a pharmacokinetic study of oxybutynin ... in the US for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). About Oxybutynin Chloride Topical Gel (OTG) OTG is a clear, ...

Neurocrine Biosciences Presents Elagolix Data

... pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the ...

Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density

... arzoxifene and placebo groups (arzoxifene 12%, placebo 11%, p=0.87). There were no significant differences in the incidence of endometrial hyperplasia or cancer between the arzoxifene and placebo groups, as assessed by serial endometrial biopsy (arzoxifene 0, placebo 2) or in endometrial thickness, ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... that RAPAFLO (TM) (silodosin), the company's new, uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), is available for patients by prescription. Watson received U.S. Food and Drug Administration (FDA) approval for RAPAFLO(TM) in October 2008. ...

Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain

... address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news ...

Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis

... reporting one or more adverse events, including vaginal bleeding, did not differ between treatment groups. No cases of endometrial polyps, hyperplasia or cancer were reported. Nasopharyngitis and bronchitis were reported more frequently with arzoxifene versus raloxifene (10.1 percent vs. 2.5 ...

Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma

... implications for patient morbidity and even mortality. LSO has completed a Phase 1/2 trial and has initiated a Phase 2a trial in benign prostatic hyperplasia (BPH), or enlargement of the prostate. The company has positioned itself for growth with a strong portfolio of intellectual property, innovation ...

Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

... pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the ...

Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis

... pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the ...

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia

... orally bioavailable small molecule, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), to treat benign prostatic hyperplasia (BPH). The abstract (#2041), "Preclinical Validation of the Trp-p8 Ion Channel as a Target for Benign Prostatic Hyperplasia," is being presented at ...

XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting

... The in-stent late loss for CUSTOM III at six-month follow-up was 0.17 mm, the in-stent binary restenosis rate was 4.4 percent, and the neointimal hyperplasia (NIH) volume was 3.8 percent. "The CUSTOM III results are very promising and demonstrate the safety of in situ customization for treatment of ...

Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15)

... SEATTLE, May 9 /PRNewswire-USNewswire/ -- The risk of the two major prostate diseases, cancer and benign prostatic hyperplasia (BPH), can be reduced by changes in lifestyle, such as avoiding smoking, maintaining a normal weight and eating a healthy diet. Alan Kristal, ...

Neurocrine Biosciences Reports First Quarter 2008 Results

... pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Indiplon was licensed from DOV Pharmaceuticals in 1998. Neurocrine ...

Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges

... of the magnitude identified in this study are troubling side effects of treatment that need to be monitored and managed." Benign prostatic hyperplasia (BPH), or an enlarged prostate gland, is a condition affecting half of men over age 50 and 80 percent of those over 70. Symptoms include difficult ...

Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil

... continuing its development of udenafil for erectile dysfunction in the USA and will develop udenafil for other indications such as benign prostatic hyperplasia and pulmonary hypertension." Ms. Ursula Falk, Managing Director of Dr. Falk Pharma commented, "Our partnership with Dong-A PharmTech for the ...

Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia

... (FDA). Watson is seeking marketing approval of silodosin from the FDA for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate. Watson anticipates that the FDA will take action on its application in the fourth quarter 2008. Silodosin was designed ...

BioVascular Inc. Closes $10.87 Million Series C Financing

... first step in a sequence of events that involve platelet aggregation and activation and may thereby prevent subsequent thrombus formation and intimal hyperplasia that occurs in a range of vascular surgical and endovascular procedures. Saratin is currently being studied in two Phase I/II clinical trials. ...

Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial

... or collagen, the platelet releases serotonin, which, based on preclinical studies, promotes platelet aggregation, vasoconstriction and intimal hyperplasia (or thickening of the vessel wall). By blocking activation of the 5-HT2A receptor on platelets and other cardiovascular tissues, APD791 may curb ...

Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years

... AVODART and tamsulosin combination therapy, AVODART monotherapy, or tamsulosin monotherapy. Enlarged prostate (also known as benign prostatic hyperplasia (BPH)), is a condition that affects 50 percent of men over the age of 50 and more than 90 percent of men over age 80. AVODART belongs to a class of ...

'Use it or Lose it': A New Theory About Preserving Erectile Function After Prostate Surgery

... in the 48-page report: -- Alternative therapies for prostate cancer -- Handling a prostate cancer relapse -- Surgical options for benign prostatic hyperplasia A year's subscription to Perspectives on Prostate Disease is available for $99 (for print and electronic versions; $89 for electronic only) ...

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting

... antagonist, ozarelix, in benign prostatic hyperplasia (BPH). Results indicate that ozarelix was well ... oncology market. About Benign Prostatic hyperplasia Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the ...

Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia

... Corporation (NASDAQ: NYMX) today announced positive results from its newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 26 clinical trial sites across the U.S. and 116 unselected subjects participated in the blinded, placebo controlled study. The study assessed ...

AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial

... positive results for a Phase 2a trial with cetrorelix in benign prostatic hyperplasia (BPH) initiated in 2005 in Japan. Results showed that cetrorelix, the ... efficacy trends for statistical significance. About Benign Prostatic hyperplasia BPH is characterized by an abnormal benign growth of the prostatic ...

Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH

... 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today completion of a new 42 month follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's two Phase 1-2 studies initiated in 2003. Individuals in ...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

... incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis and veno-occlusive lesions. Hepatic vascular disorders should be considered and, ...

Celsion Completes Enrollment in Phase I Liver Cancer Study

... Health System. Celsion has also developed a microwave based system, the Prolieve Thermodilatation(R) system, for the treatment of benign prostatic hyperplasia which is marketed in the United States under an exclusive distribution agreement with Boston Scientific Corporation. For more information on Celsion, ...

Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial

... estrogen receptor beta agonist that is expected not to stimulate the endometrium or breast tissue. Safety analyses showed no cases of endometrial hyperplasia or uterine cancer during the trial and there were no differences in incidence of vaginal bleeding between the placebo group and the two cohorts ...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

... The incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis and veno-occlusive lesions. Hepatic vascular disorders should be considered and, if ...

Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings

... Corporation (NASDAQ: NYMX) today announced that detailed results from the Company's recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at a series of upcoming U.S. urology meetings, beginning in September at the South Central American Urological Association ...

Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings

... (NASDAQ: NYMX) today announced that detailed results from the Company’s recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at a series of upcoming U.S. urology meetings, beginning in September at the South Central American Urological Association ...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

... (under age 45) more than twice as likely to develop breast cancer compared to women diagnosed with atypia after 55. The number of areas of atypical hyperplasia was significant as well. With one area of atypia, breast cancer risk was 2.3-fold compared to the general population; this risk more than ...

Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting

... Corporation (NASDAQ: NYMX) today announced that further clinical results from the Company's studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the New England Section of the American Urological Association Meeting in Boston in September. The paper is authored by ...

Protox Announces Positive Clinical Data from Prostate Cancer Study

... PRX302 (PORxin) for the treatment of localized prostate cancer. A Phase 1 clinical trial evaluating PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate) is ongoing. NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES ...